Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: BDC Laboratories, Dialcare, Exact Sciences, Freenome, GE Healthcare, Gentuity, Helix, Nanovibronix, Orchestra Biomed, Reshape Lifesciences, Veracyte, Vyome, Zelis.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Instylla, Surgibox, Zien Medical.
A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at approximately $2.25 billion. The funding will support expansion of the Edison Histotripsy system and therapy platform into new clinical indications and markets. Edison uses non-invasive focused ultrasound energy to destroy tumors.
The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed acquisition of Jenavalve because Edwards’ acquisition of both Jenavalve Technology Inc. and JC Medical would eliminate competition in the TAVR space for aortic regurgitation.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bionano, Bridge to Life, Caredx, Implantica, Paragonix.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Daxor, Deephealth, Instylla, Pearl Diagnostics, Thermo Fisher Scientific.
With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, biopharma companies are building treasuries of digital assets to secure future R&D efforts and operational runways. Companies such as Artelo Biosciences Inc., MEI Pharma Inc., Windtree Therapeutics Inc. and 180 Life Sciences Corp. and have entered crypto deals in recent weeks, with the latter noting the potential to “unlock value outside traditional biotech milestones.”
RSS
